公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2012 | A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II | Mok, Tony; Wu, Yi Long; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia Elena; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Jin, Kate; Truman, Matt; Lee, Jin Soo; 余忠仁 | J. Clin. Oncol. | | | |
2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |